Clinical Trial Update: Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for a combination of rituximab, acalabrutinib, and durvalumab (RAD) in primary central nervous system lymphoma, currently listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Acalabrutinib (Calquence) (acalabrutinib)
• Durvalumab (Imfinzi) (durvalumab)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Primary Central Nervous System Lymphoma (PCNSL) | Phase 1 | Status: ACTIVE_NOT_RECRUITING